Renal Cell Carcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 59 expanded access programs, clinical trials, and compassionate use pathways listed for Renal Cell Carcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with renal cell carcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 22 programs are currently active or recruiting, with the remaining 37 in other lifecycle stages. Sponsors actively running programs in this area include Merck Sharp & Dohme LLC, M.D. Anderson Cancer Center, University of Texas Southwestern Medical Center, Bristol-Myers Squibb, Dana-Farber Cancer Institute, and others.
By recruiting status
Snapshot of where every Renal Cell Carcinoma program currently sits in its lifecycle.
- Active / Recruiting22
- Inactive37
Top sponsors
Organisations running the most Renal Cell Carcinoma programs in the directory.
- Merck Sharp & Dohme LLC6 programs
- M.D. Anderson Cancer Center4 programs
- University of Texas Southwestern Medical Center3 programs
- Bristol-Myers Squibb2 programs
- Dana-Farber Cancer Institute2 programs
- Hoffmann-La Roche2 programs
- Mayo Clinic2 programs
- National Cancer Institute (NCI)2 programs
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2 programs
- Yale University2 programs
Renal Cell Carcinoma programs (59)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Belzutifan and Zanzalintinib for Recurrent Kidney Cancer After Previous Treatment — Merck Sharp & Dohme LLC
- Study on Cemiplimab and Fianlimab for People with Clear Cell Kidney Cancer — Memorial Sloan Kettering Cancer Center
- Study on Nivolumab and Cabozantinib Compared to Sunitinib for Untreated Advanced or Metastatic Kidney Cancer — Bristol-Myers Squibb
- Study Comparing Nivolumab and Ipilimumab Combination to Nivolumab Alone in Advanced Kidney Cancer — Bristol-Myers Squibb
- Study on the Safety and Effectiveness of A2B395 CAR T-Cell Therapy for Solid Tumors with Specific Genetic Markers — A2 Biotherapeutics Inc.
- Study on the Safety of AZD6750 for Adults with Advanced or Metastatic Solid Tumors — AstraZeneca
- Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
- Study on Cabozantinib-S-Malate for Treating Young Patients with Sarcomas, Wilms Tumor, or Other Rare Tumors — National Cancer Institute (NCI)
- Study on High Dose IL-2 and Entinostat for Kidney Cancer — Roberto Pili
- Study on Pre-Surgery Radiation Therapy for Kidney Cancer with Tumor in the Vena Cava — University of Texas Southwestern Medical Center
- Study on Cabozantinib Before Surgery for Locally Advanced Kidney Cancer — Emory University
- Study on Patient Preference for Subcutaneous vs. Intravenous Immune Therapy — Diwakar Davar
- Study on the Safety and Effectiveness of ST-067 in Patients with Advanced Solid Tumors — Simcha IL-18, Inc.
- Study on Neoadjuvant HIF-Inhibitor Immunotherapy for Kidney Cancer — Dana-Farber Cancer Institute
- Study on Pre-Surgery Use of Sutent for Kidney Cancer — M.D. Anderson Cancer Center
- Study on Retifanlimab and Ruxolitinib for Advanced Kidney and Lung Cancers — University of California, San Diego
- Study on Proton-Based Stereotactic Radiation Therapy for Treating Kidney Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Cabozantinib with Nivolumab and Ipilimumab for Untreated Advanced or Metastatic Kidney Cancer — Exelixis
- Study on High Dose Interleukin-2 (IL-2) and Targeted Radiation Therapy for Patients with Metastatic Kidney Cancer — Providence Health & Services
- Study of Nivolumab and Axitinib for Patients with Advanced Kidney Cancer — Fox Chase Cancer Center
- Study on Combination Therapies for Kidney Cancer That Returns During or After Anti-PD-(L)1 Treatment — Merck Sharp & Dohme LLC
- Home-Based Cancer Treatment Program for Patients in the Florida Panhandle and Nearby Areas — Mayo Clinic
- Study on 89Zr-DFO-Atezolizumab PET/CT Scans for Patients with Advanced or Metastatic Kidney Cancer — James Brugarolas
- Phase 2 Study of Sasanlimab, Palbociclib, and Axitinib for Advanced Kidney Cancer — Stephanie Berg
- Phase II Study of Nivolumab, Ipilimumab, and Cabozantinib for Untreated Kidney Cancer with Brain Metastases — M.D. Anderson Cancer Center
- Study on V940 and Pembrolizumab for Kidney Cancer (V940-004) — Merck Sharp & Dohme LLC
- Study on Belzutifan with Palbociclib vs. Belzutifan Alone for Advanced Kidney Cancer — Merck Sharp & Dohme LLC
- Study on Immune Checkpoint Inhibitor Combinations with Axitinib for Untreated Advanced Kidney Cancer — Hoffmann-La Roche
- A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma — NiKang Therapeutics, Inc.
- Study on Oral Alintegimod with Ipilimumab and Nivolumab for Cancer Treatment — 7 Hills Pharma, LLC
- Study on Patient Preference for Subcutaneous vs. Intravenous Pembrolizumab in Various Cancers — Merck Sharp & Dohme LLC
- Study on Pazopanib With or Without Abexinostat for Advanced or Metastatic Kidney Cancer (RENAVIV) — Xynomic Pharmaceuticals, Inc.
- Study on Using a Recombinant Virus with Cemiplimab for Treating Kidney Cancer — SillaJen, Inc.
- A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors — Eutilex
- Study on Cabozantinib Combined with Nivolumab and Ipilimumab for Advanced Kidney Cancer — Bradley A. McGregor, MD
- Study Comparing In-Home and In-Clinic Administration of Nivolumab for Cancer Patients — Mayo Clinic
- Study on Kidney Cancer Surgery Combined with Immunotherapy and Targeted Therapy — Mark Stein
- Early Access Program for HER2/HER3 Bispecific Antibody MCLA-128 for Patients with Advanced NRG1-Fusion Positive Solid Tumors — Merus N.V.
- Study on GI-101 Alone or with Pembrolizumab, Lenvatinib, or Local Radiotherapy for Advanced Solid Tumors — GI Innovation, Inc.
- Phase 2 Study of 177Lu-PSMA-617 for Treating Advanced Kidney Cancer — Dana-Farber Cancer Institute
- Study on Using Molecular Residual Disease to Guide Additional Therapy in Kidney Cancer — University of Alabama at Birmingham
- Study on Lenvatinib and Pembrolizumab Before Surgery for Kidney Cancer with IVC Tumor Thrombus — University of Texas Southwestern Medical Center
- Study on Pembrolizumab and Axitinib Before Surgery for Kidney Cancer with Tumor in the Main Vein — University of Colorado, Denver
- Study on Pembrolizumab and Lenvatinib for Patients with Brain Metastases from Melanoma or Kidney Cancer — Yale University
- Study on Ipilimumab, Nivolumab, and Ciforadenant for First-line Treatment of Advanced Kidney Cancer — M.D. Anderson Cancer Center
- Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma — M.D. Anderson Cancer Center
- Study on PRO1160 for Treating Advanced Solid and Liquid Tumors — ProfoundBio US Co.
- Study on Combination Immunotherapies for Patients Previously Treated with Immune Checkpoint Inhibitors — ImmunityBio, Inc.
- Study on the Safety and Effectiveness of NEO212 for Patients with Certain Brain Tumors or Brain Metastasis — Neonc Technologies, Inc.
- Study on the Safety and Effectiveness of Pembrolizumab for Kidney Cancer After Surgery — Merck Sharp & Dohme LLC
- Study on Sequential Treatment with Cabozantinib or Cabozantinib and Nivolumab for Advanced Kidney Cancer — University of Texas Southwestern Medical Center
- Study on Adaptive Immunotherapy with VEGFR-TKI for Patients with Advanced Kidney Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Study on INBRX-106 Alone and with Pembrolizumab (Keytruda®) for Advanced Solid Tumors — Inhibrx Biosciences, Inc
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT for Advanced or Metastatic Cancers — ImaginAb, Inc.
- Study Comparing Tivozanib with Nivolumab to Tivozanib Alone in Patients with Advanced Kidney Cancer — AVEO Pharmaceuticals, Inc.
- Study on Bevacizumab, Erlotinib, and Atezolizumab Combination for Advanced Kidney Cancer — National Cancer Institute (NCI)
- Study on Stereotactic Body Radiation Therapy for Limited Progression in Metastatic Kidney Cancer Patients on Immune Checkpoint Inhibitors — Yale University
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Renal Cell Carcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.